Nurse Practitioner Program year 2023 Source: CMS Open Payments, 2026 publication

Amanda Jakositz

Nurse Practitioner Everett, WA Nurse Practitioner

NPI 1588089791 CMS profile 11025014

3901 Hoyt Ave, Everett, WA 98201

Open in the dashboard

General payments

$85

1 record reported · program year 2023

Research payments

$0

Paid to them · None reported · program year 2023

Ownership & investment interest

$0

None reported

Through program year 2023, Amanda Jakositz of Everett, WA is reported in the CMS Open Payments database as having received $85 across 1 general payment and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 23rd percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

1 row
Year Kind Relative to this record's peak year Amount Records
2023 General $85 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amanda Jakositz
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Amanda Jakositz were reported at $0. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Amanda Jakositz Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $0 $135 $40–$426 $132
2022 $0 $152 $48–$470 $149
2023 $85 $166 $54–$529 $160
2024 $0 $173 $55–$556 $164
2025 $0 $174 $55–$557 $169

Breakdown

Who paid General payments · program year 2023
  1. AstraZeneca Pharmaceuticals LP $85 1 payment

Every payment, record by record

What the payments were for General payments · program year 2023
  1. Food and Beverage $85 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 36 drugs

Part D claims

1,643

Median for Nurse Practitioner: 389

Drug cost

$382,207

Median for Nurse Practitioner: $21,885

Branded share of claims

52.1%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Spiriva Respimat Tiotropium Bromide Brand 61 $63,856
Spiriva Handihaler Tiotropium Bromide Brand 40 $49,255
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 39 $31,240
Breo Ellipta Fluticasone/Vilanterol Brand 28 $26,996
Arnuity Ellipta Fluticasone Furoate Brand 42 $25,195
Combivent Respimat Ipratropium/Albuterol Sulfate Brand 33 $24,515
Incruse Ellipta Umeclidinium Bromide Brand 38 $23,506
Symbicort Budesonide/Formoterol Fumarate Brand 43 $21,950
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 19 $20,075
Advair Hfa Fluticasone Propion/Salmeterol Brand 40 $20,062

The 10 drugs with the highest cost, of 36 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 23 billing codes

Paid by Medicare

$29,497

Medicare's payments for the services billed

Medicare patients

320

Average age 74

Services billed

479

155 women, 165 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 45%
Chronic kidney disease 33%
Diabetes 31%
Ischemic heart disease 27%
Depression 25%
Atrial fibrillation 20%
Heart failure 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

1 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Washington

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record